Artemis Therapeutics Inc. (OTCMKTS:ATMS – Get Rating) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,300 shares, a decline of 27.8% from the June 15th total of 1,800 shares. Based on an average daily volume of 900 shares, the days-to-cover ratio is presently 1.4 days.
Artemis Therapeutics Price Performance
Artemis Therapeutics stock opened at $3.75 on Monday. Artemis Therapeutics has a twelve month low of $0.55 and a twelve month high of $6.00. The stock's fifty day simple moving average is $3.59 and its 200-day simple moving average is $2.02.
Get Artemis Therapeutics alerts:Artemis Therapeutics (OTCMKTS:ATMS – Get Rating) last posted its quarterly earnings data on Monday, May 23rd. The company reported ($0.01) earnings per share for the quarter.
About Artemis Therapeutics
(Get Rating)Artemis Therapeutics Inc does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc is a subsidiary of Tonak Ltd.
See Also
- Get a free copy of the StockNews.com research report on Artemis Therapeutics (ATMS)
- Financial services firm Block stock has fallen (-59%) in 2022
- Hold Pfizer Today With Catalysts for Further Growth Tomorrow
- NVIDIA Stock is a Winding Up for a Record Setting Second Half
- Johnson & Johnson Continues to Prove its Value in a Volatile Year
- MarketBeat: Week in Review 7/11 – 7/15
Receive News & Ratings for Artemis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artemis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.